Bayer Stock: German Drug-Pricing Reform and Glyphosat Delay Form a Two-Pronged Test

Bayer shares surged 83% in 12 months but face German drug discount vote and Roundup settlement delay. RSI at 73 signals overbought; earnings on Aug 4.

Bayer’s recent rally is running into a pair of obstacles that are playing out on different sides of the Atlantic. German lawmakers are voting on a healthcare bill that would dramatically hike the mandatory discount on patented medicines, while a proposed $7.25 billion settlement for Roundup claims has been pushed back to August. Despite the twin uncertainties, the stock has been on a tear.

The Bundestag on Friday is holding a recorded vote on the GKV-Beitragssatzstabilisierungsgesetz, a measure aimed at closing a projected €15.3 billion shortfall in statutory health insurance by 2027. The original cabinet draft had pegged the industry’s burden at €1.2 billion, but the parliamentary version now stands at roughly €4.1 billion. The centerpiece is a one-off increase in the manufacturer discount on patent-protected drugs from 7% to 15.5%. Additional measures include a 50% tightening of the price-volume regulation, a higher vaccine rebate, and a price moratorium running through 2030. The Research-Based Pharmaceutical Companies Association (vfa) has warned that the combined extra costs could reach €4.5 billion by the end of the decade, and criticizes the industry as the only payer group that has not been spared. The GKV-Spitzenverband counters that historical rebates have been as high as 17%.

Meanwhile, the legal front in the United States has shifted. A federal judge had been expected to rule on July 9 on the preliminary approval of Bayer’s $7.25 billion deal to resolve a majority of outstanding Roundup claims filed in state courts. That decision has now been rescheduled to August 19. In the run-up, a fairness hearing was held, and Bayer is also pushing to consolidate nearly 4,000 individual claims currently before a federal court in San Francisco. The plaintiffs continue to argue that Roundup causes cancer, a claim Bayer disputes based on its own studies. A recent U.S. Supreme Court ruling strengthened federal preemption of state labeling requirements for pesticides, prompting plaintiffs to pivot to allegations of design defects and negligence.

Against this backdrop, the stock has delivered striking performance. Bayer shares closed Thursday at €50.70, up 33% since the start of the year and 83% over the past twelve months. The 30-day gain alone stands at 44%. On July 3, the stock hit a 52-week high of €53.86, but has since eased 4.41% on a weekly basis. Still, that high is less than 6% above the current price.

Technical indicators suggest the rally has become stretched. The relative strength index sits at 73.0, a level that typically signals overbought conditions. With an annualized volatility of 63.12%, the shares are prone to sharp swings. Any surprise from Berlin — or a fresh delay in the Roundup settlement — could trigger a rapid reversal.

Two events now dominate Bayer’s near-term calendar. On August 4, the company is scheduled to report second-quarter earnings for 2026. Exactly two weeks later, on August 19, the court will revisit the proposed Roundup settlement. Both dates could determine whether the rally has further room to run or whether the political and legal headwinds finally catch up.